Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of favipiravir in treatment of coronavirus infection

a coronavirus and favipiravir technology, applied in the field of coronavirus infection treatment with favipiravir, can solve the problems of high death probability and dysfunction of the death organ

Inactive Publication Date: 2021-07-22
ACADEMY OF MILITARY MEDICAL SCI
View PDF0 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The patent is about using Favipiravir to treat infections caused by the coronavirus, specifically SARS-CoV-2. The patent describes the use of Favipiravir in treating infections caused by the coronavirus, specifically SARS-CoV-2. The patent describes the effectiveness of Favipiravir in inhibiting the virus in animal models and the lack of cytotoxicity in certain cells. The patent also describes the use of Favipiravir in treating patients with SARS-CoV-2 infection. The technical effect of the patent is the use of Favipiravir to treat infections caused by the coronavirus, specifically SARS-CoV-2.

Problems solved by technology

Patients with sepsis often have fatal organ dysfunction, and the most critical patients are those with septic shock, and they may have a high probability of death.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of favipiravir in treatment of coronavirus infection
  • Use of favipiravir in treatment of coronavirus infection
  • Use of favipiravir in treatment of coronavirus infection

Examples

Experimental program
Comparison scheme
Effect test

example 2

Experiment of Favipiravir in Protecting SARS Coronavirus-Infected Mice from Death

[0097](1) Grouping and Marking of Mice

[0098]A129 mice aged 3-4 weeks and weighed 9-13 g (provided by Institut Pasteur of Shanghai, Chinese Academy of Sciences) were randomly divided into 4 groups, namely the virus control group, the high-dose administration group, the middle-dose administration group and the low-dose administration group, 10 mice per group, marked with ear studs.

[0099](2) Preparation of Drug

[0100]0.5% CMC-Na was used as solvent to dissolve Favipiravir. First, the drug Favipiravir was accurately weighed, added with an appropriate amount of 0.5% CMC-Na solution, alternately treated under vortex and ultrasonic condition for 15 min until the sample was a uniform particle suspension, then diluted with 0.5% CMC-Na by 2-fold, and the dilution was carried out according to administration dose of 200 mg / kg, 100 mg / kg and 50 mg / kg, respectively. The resultant drug solutions were stored at 4° C. fo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Fractionaaaaaaaaaa
Login to View More

Abstract

The present application relates to a Favipiravir compound represented by Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate and / or a hydrate thereof, and a pharmaceutical composition comprising the compound for treating a coronavirus infection.

Description

[0001]The present application is based on and claims the benefit of priority from Chinese application No. 202010070142.0, filed on Jan. 21, 2020, the disclosure of which is incorporated herein by reference in its entirety.REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY[0002]The content of the electronically submitted substitute sequence listing, file name 2020-10-13_SeqListing_3274-0290001.txt, size 631 bytes; and date of creation Oct. 13, 2020, filed herewith, is incorporated herein by reference in its entirety.TECHNICAL FIELD[0003]The present application relates to use of Favipiravir represented by the following Formula I, a geometric isomer, a pharmaceutically acceptable salt, a solvate, and / or a hydrate thereof, and a pharmaceutical composition comprising the above compound, in treating an infection caused by a coronavirus, especially SARS coronavirus (SARS-CoV) and SARS-CoV-2.BACKGROUND ART[0004]Favipiravir (compound represented by Formula I, T-705) with chemical name of...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/4965A61P31/14
CPCA61K31/4965A61P31/14A61P11/00
Inventor ZHONG, WUCAO, RUIYUANCAO, CHENGGAO, TINGXIAO, GENGFUHU, ZHIHONGWANG, MANLIZHANG, LEIKELI, SONG
Owner ACADEMY OF MILITARY MEDICAL SCI
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com